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Title 
Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical 
Research Collaboration 
 
ONLINE SUPPLEMENT 
 
METHODS 
Ethical approval was waived for the active involvement of patients as either advisors or 
participants in questionnaires. In considering patients as advisors, the European Lung 
Foundation (ELF) adheres to the same guiding principles as the UK’s NHS patient and public 
involvement body INVOLVE (http://www.invo.org.uk/wp-
content/uploads/2011/12/INVOLVENRESfinalStatement310309.pdf). According to these 
principles, the active involvement of patients does not generally raise any ethical concerns for 
the people who are actively involved because they are not acting in the same way as research 
participants. They are acting as specialist advisers, providing valuable knowledge and expertise 
based on their experience of a health condition. Therefore ethical approval is not needed for 
the active involvement element of the research, where people are involved in planning or 
advising on research e.g. helping to develop a protocol, questionnaire or information sheet, 
member of advisory group, or co-applicant. Furthermore, the patients involved as advisors in 
the present project were not involved in carrying out research that involves direct contact with 
study participants e.g. helping to analyse survey data, or communicate directly with survey 
respondents.   
In considering patients as study participants, ethics committee approval is not generally 
required for online questionnaires as the methodology is considered to pose a minimal risk to 
the participant. However, ELF adheres to strict ethical principles in questionnaire design, data 
collection and analysis: transparency of purpose and inclusion/exclusion criteria is always 
provided at the start of the questionnaire, with a contact name and email address for an ELF 
staff member provided, so that questions can be asked or any concerns raised. Respondents 
were free to skip questions and leave the questionnaire/project at any time. The questionnaires 
were anonymous, as respondents chose to provide a contact email address, e.g. when asked at 
the end of the questionnaire if they ‘would like to receive updates on the project or get 
involved and represent others with bronchiectasis.’ All questionnaire data are stored and 
password protected on the ELF server, and only accessible by ELF staff members. 
 
 
 
 
 
 
FIGURES 
 
Figure A: Questionnaire respondents by country. 
Footnotes: n= percentage of respondents.  
 
Figure B: Questionnaire respondent status (patient, parent, relative, carer, or friend of 
someone with bronchiectasis). 
Footnotes: n= percentage of respondents.  
 
Figure C: Questionnaire respondents by age. 
Footnotes: n= percentage of respondents.  
 
Figure D: Research topics (in order of importance) to improve how bronchiectasis is managed 
by doctors. 
Footnotes: n= percentage of respondents. NCFBE: non cystic fibrosis bronchiectasis 
 
 
Figure E: Research topics (in order of importance) to improve how bronchiectasis is treated. 
Footnotes: n= percentage of respondents. NCFBE: non-cystic fibrosis bronchiectasis 
 
Figure F: Research topics (in order of importance) to improve how each person’s 
bronchiectasis is monitored.  
Footnotes: n= percentage of respondents. CT: computed tomography; NCFBE: non-cystic 
fibrosis bronchiectasis 
 
Figure G: Research topics (in order of importance) to improve self-management throughout 
life. 
Footnotes: n= percentage of respondents. HCP: health-care professionals. 
 
 
 
 
FULL DISCUSSION OF RESEARCH PRIORITIES 
 
Research priorities commonly identified by both experts and patients 
 
1. What are the causes of bronchiectasis? (Patients) / What are the baseline investigations to 
evaluate etiologies in patients with bronchiectasis? (Experts) 
 
One of the cornerstones in the management of bronchiectasis is the identification and 
treatment of underlying causes. Several predisposing factors might be identified including 
previous severe respiratory infections, allergic bronchopulmonary aspergillosis, impairment of 
ciliary clearance, primary or secondary immunodeficiency, and other diseases associated to 
bronchiectasis, such COPD and severe asthma. Despite following guidelines recommendations, 
an etiology of bronchiectasis cannot be reached in 40% of the patients, whilst an etiology of 
bronchiectasis leading to a change in patient’s management may be identified in only 13% of 
the cases [1]. Three of the top five ranked priorities in the questionnaire called for research into 
the causes and development of bronchiectasis: how bronchiectasis develops and continues; 
what makes some patients’ deteriorate and the causes of bronchiectasis. Many open responses 
also related to this topic, particularly in the calls for research into genetic factors in the 
development of the condition, and ultimate hope for a cure [2,3]. The respondents strongly 
support both research on the causes of the condition, and to slow and prevent the 
development of bronchiectasis and its symptoms [4]. Further research should integrate basic 
research from the “-omics” perspective with clinical data in order to identify the possible 
etiologies among the large group of patients with idiopathic bronchiectasis. An early example of 
this was recently published by Szymanski et al. who used exome sequencing to identify 
multigenic susceptibility factors for bronchiectasis associated with NTM disease [5].  
Consensus statements:  1) DNA biobanks linked to well phenotyped patient cohorts should be 
established to enable underlying genetic susceptibility to bronchiectasis to be established; 2) 
Observational research in large patient cohorts is needed to establish the natural history of 
bronchiectasis due to different aetiologies. 
 
 
2. What are the triggers of an exacerbation? (Patients) / What are the causes of an 
exacerbation of bronchiectasis? (Experts) 
 
Exacerbations of bronchiectasis are characterized by increases in cough frequency, sputum 
volume and purulence and represent a significant cause of morbidity in bronchiectasis [6,7].  
Pulmonary exacerbations are associated with disease progression and frequent or severe 
exacerbations are an independent risk factor for mortality. The respondents strongly support 
research into the triggers of exacerbation and expanded on this priority by calling for research 
to focus on the need to reduce the frequency, duration and severity of exacerbations.  
Although in asthma and COPD the presence and prevalence of non-infectious triggers of 
exacerbations have been recognized during the past decade, these data are still missing in 
bronchiectasis [8]. The “vicious-cycle” hypothesis that characterized the physiopathology of 
bronchiectasis patients in stable state does not rule out the possibility that non-infectious 
triggers, including indoor and outdoor air pollution, might cause exacerbations and further 
prospective observational studies are needed in this area [9]. 
From an infective point of view, changes in airway bacterial community composition, 
emergence of new strains, as well as spread of infection by the same species to new regions of 
the lung might trigger exacerbations [10-12]. The most common organisms seen during an 
exacerbation are P. aeruginosa, H. influenzae, S. pneumoniae, S. aureus and M. catarrhalis [13, 
14]. The need of moving beyond conventional microbiological techniques has been suggested 
by the following observations: a) total bacterial density seems not to increase significantly at 
the onset of exacerbation in comparison to stable state; b) patients might show a good clinical 
response when an antibiotic not targeted on the colonizing pathogen has used and that 
pathogens are frequently isolated in stable patients [15]. New airway infection caused by 
organisms present in low abundance (and thus that may be not detected with conventional 
techniques) yet identifiable by metagenomic approaches could help us understand what is 
responsible for triggering a new exacerbation [15]. However, it could be also possible that 
exacerbations may also be driven by changes and/or adaptation in strains that cannot be 
detected by such approaches and hence a metabolomics approach may help. 
Finally, the role of viruses in triggering infective exacerbations should also be better defined. 
Coronavirus, rhinovirus and influenza A/B seem to be the most common viruses identified 
during an exacerbation and virus-positive exacerbations are associated with high levels of 
systemic and airway inflammation [16]. The interaction between respiratory viruses and 
bacteria in stable and acute exacerbation of bronchiectasis should be also investigated in light 
of previous evidence suggesting that respiratory viruses may precipitate secondary bacterial 
infection in COPD and CF [17, 18]. 
Consensus statement: A comprehensive study enrolling patients when stable and during 
exacerbation should be conducted, evaluating the impact of bacteria, viruses, fungi and non-
infectious stimuli to identify the cause(s) of bronchiectasis exacerbations.  
  
 
3. How can we improve the access to physio and home-use techniques? (Patients) / When 
should airways drainage techniques be started in patients with bronchiectasis and which one is 
the most effective and pragmatic? (Experts) 
 
Impaired mucociliary clearance is one of the key characteristics of bronchiectasis [19].  
Interventions aimed at promoting clearance of excess mucus are therefore a mainstay of 
management. Consensus guideline suggest that all patients with bronchiectasis should receive 
instructions on performing physiotherapy and healthcare workers should tailor different 
techniques to patients’ preference in order to increase patients’ adherence [20]. Few studies 
have explored the impact of physiotherapy in bronchiectasis. A recent Cochrane review 
evaluated five trials with a total of 51 participants and indicated that airway clearance 
techniques are safe and allow a better sputum expectoration with an increase in patients’ 
quality of life [21]. Current guidelines on bronchiectasis also recommend pulmonary 
rehabilitation, in order to improve exercise tolerance and quality of life. Although evidence on 
pulmonary rehabilitation is scarce, most of the studies demonstrated an increase in patients’ 
performance and quality of life, and an increase of the time to the next exacerbation [22-24]. A 
study of 75 patients with bronchiectasis indicated that only 41% of patients were adherent to 
prescribed chest clearance regimes [25]. Both physicians and patients agreed that additional 
controlled trials of these interventions would be beneficial but that the priority may be in 
identifying methods that are accessible and that encourage adherence.  
Consensus statement: Studies are required to optimize compliance and access to chest 
physiotherapy and pulmonary rehabilitation in bronchiectasis. 
 
 
4. Identify patients at risk of poor outcomes (Patients) / What are the risk factors and causes for 
fast progression and poor outcomes in patients with bronchiectasis? (Experts) 
 From both patient and experts’ perspective, it is crucial that healthcare workers can identify 
which patients are at greater risk of poor outcomes and in need of urgent treatment [26]. 
Recently, two scores have been proposed to predict adverse outcomes in bronchiectasis: the 
Bronchiectasis Severity Index (BSI) and the FACED score [27]. The BSI has been shown to 
accurately identify patients at the highest risk of complications, including exacerbations and 
impaired quality of life, and so far is the only prediction tool for bronchiectasis that has been 
externally validated in large cohorts. Expert opinion suggests that disease severity may be 
useful as a framework for clinical decision allowing the appropriate targeting of therapies 
including long-term macrolides, inhaled antibiotic treatment and airway adjuncts. Clinical 
prediction tools require to be internationally validated and then to demonstrate improvements 
in clinical management after implementation into clinical practice.  
In case of progressive decline in lung function, respiratory failure and diffuse disease, lung 
transplantation might be a therapeutic option with suitable long-term survival and an 
improvement in quality of life in appropriately selected patients [28]. An accurate assessment 
of prognosis is essential for rational decisions regarding transplantation in bronchiectasis, and 
scoring may also be helpful in this context [29]. 
Several other factors need future multicentre, prospective, longitudinal studies to evaluate 
drivers of faster disease progression including the evaluation of microorganisms other than P. 
aeruginosa, microbiome parameters such as species diversity and richness, local and systemic 
inflammatory biomarkers and, other measurements of lung function impairment (e.g. lung 
clearance index). The importance of comorbidities should also be explored as they may be 
amenable to treatment [30]. 
Consensus statements: 1) A deeper understanding of the inflammatory pathways in 
bronchiectasis is needed to develop new therapies. We recommend using emerging 
techniques and technologies (particularly proteomics, metabolomics and genomics) in large 
well-characterized cohorts to identify new treatment targets and deeper patient 
phenotyping; 2) An implementation study should be performed to demonstrate if the use of 
bronchiectasis severity scores could improve patient care. 
 
 
 
Important research priorities identified by experts 
 
1. When and how should Pseudomonas aeruginosa be eradicated in patients with bronchiectasis 
and does eradication result in improved outcomes? 
 
Pseudomonas aeruginosa is persistently isolated in up to 35% of patients with bronchiectasis. A 
recent study found that P. aeruginosa colonization is associated with a 3-fold increase risk of 
death, a nearly 7-fold increase risk of hospital admissions, worse quality of life and more 
frequent exacerbations [31]. Evidence from CF suggests that attempts at eradication therapy 
targeting Pseudomonas can have success in converting patients to culture negative status [32]. 
The data both in bronchiectasis and CF are of limited quality in defining both the early 
outcomes and long-term benefits. There are no large adequately powered studies to inform 
current practice, with most studies limited to observational case series [33,34]. Difficulties 
remain in determining the correct population to study. There is however a perception that 
patients with new acquisition of Pseudomonas may be the most amenable to eradication 
therapies. Notably, a challenging aspect for future trials designs is the recent observation that 
according to standard culture definitions Pseudomonas may “clear” spontaneously particularly 
in those with milder disease [35]. 
Other studies using inhaled antibiotics therapies focused on treating those with persistent 
infection with the primary aim of reducing exacerbations [36]. An unexpected benefit seen in 
these trials is that they have consistently demonstrated small but significant rates of 
“eradication” of up to 10-15% [37,38]. Prior “eradication” therapeutic approaches have 
included pulmonary-targeted therapies such as nebulized antibiotics. Treatment periods have 
varied dependent on the phase of development and the intent for exacerbation prevention. In 
general, new acquisition eradication studies have been shorter in duration such as 3 months 
whilst those using nebulized therapies were aiming to reduce exacerbations in those persistent 
infection have been as long as 12 months. 
From the available literature there are significant variations in all aspects of study design. 
Future randomized controlled studies will need clear definitions, techniques used and timing of 
testing for eradication. Examples of methodological variation may include culture of 
Pseudomonas at 3, 6 or 12 months on spontaneous sputa during treatment. Additional 
variables may include studying induced sputa (as inhaled antibiotic regimens do reduce sputum 
volume), using non-culture based techniques (polymerase chain reaction) for diagnosis of 
Pseudomonas persistence and variation in timing of the sampling. 
Consensus statement: A randomized controlled trial of Pseudomonas aeruginosa eradication 
therapy, compared to no eradication treatment, should be performed.  
 
 
2. What is the optimal antibiotic regimen (dosage, how many antibiotics, type, oral vs. 
intravenous vs. inhaled/nebulized, length of therapy) for an exacerbation of bronchiectasis? 
 
Most of the bronchiectasis patients experiencing an exacerbation receive antibiotics, and these 
have been proven to reduce systemic inflammation, sputum inflammatory biomarkers, sputum 
volume and purulence, and bacterial density [14]. However, data evaluating the use of 
antibiotics during an exacerbation are extremely heterogeneous in terms of the antimicrobials 
used, route of administration, duration of treatment and clinical/microbiological endpoints. 
Last but not least, there are no randomized placebo-controlled trials of antibiotic regimes 
during exacerbation.  This may be important as several classes of antibiotics have interesting 
additional effects beyond their antimicrobial actions e.g. macrolides have anti-inflammatory 
activity whilst tetracycline’s may inhibit stromal remodelling and tissue damage via their effects 
on matrix metalloproteinases. 
International guidelines suggest that both oral and intravenous antibiotic choices should be 
guided, where possible, by previous sputum microbiology. However, it should be also 
underlined that the role of antibiotic sensitivity testing in patients with bronchiectasis and 
chronic P. aeruginosa infection is contentious due to possible sampling errors (sputum plug 
from a quiescent area of the lung), hypermutation and the poor correlation between in vitro 
antibiotic sensitivity test results and clinical outcomes [39]. Clinical experience suggests that 
better outcomes are seen with higher dose oral regimens, which presumably reflects their 
superiority over conventional doses in achieving adequate antibiotic concentrations within the 
lumen of bronchiectatic airways. This is particularly relevant in the context of chronic infection 
where bacteria are often resistant and protected by biofilms. The appropriate length of 
treatment for exacerbations is also unknown, while consensus guidelines recommend 14 days 
of treatment with antibiotic therapy. The optimal duration of treatment is importance as 
prolonged treatment carries a higher risk of driving antibiotic side effects, including resistance. 
Murray and colleagues prospectively studied the effect of intravenous antibiotic therapy on 
clinical and laboratory end-points in patients with bronchiectasis exacerbations [14]. They 
demonstrated significant reductions in 24-hour sputum volume and C-reactive protein, with 
improvements in quality of life, exercise capacity and clearance of bacteria after 14 days 
treatment. Finally, the possibility of treating exacerbations of bronchiectasis with nebulized 
antibiotics has also been tested in the past [40]. Inhaled tobramycin solution was added to oral 
ciprofloxacin to treat exacerbation in the context of P. aeruginosa infection, showing a superior 
microbiological efficacy compared to ciprofloxacin alone. 
Consensus statements: 1) A randomized controlled trial comparing at least 14 days of 
antibiotic treatment for exacerbations with shorter course treatments is required.  
 
 
3. What are the prevalence and characteristics of microbiological colonization, in patients with 
bronchiectasis across Europe (including bacteria, viruses, fungi, non-tuberculous mycobacteria 
and resistant microorganisms)? 
 
Diverse polymicrobial communities exist within bronchiectasis-affected airways, causing 
chronic infection or exacerbations. H. influenzae and P. aeruginosa are the most commonly 
isolated organisms in several European studies using aerobic selective cultures, although no 
organisms are isolated in 23-27% of patients [4,15,41-43]. However, new methods to study lung 
microbiota found that the diversity of airway infection is underestimated. First of all, when 
strict anaerobic cultures are applied, anaerobic bacteria might be found in up to 83% of sputum 
samples [44]. Second, using 16S rRNA gene amplicon sequencing, three taxa, Streptococcaceae, 
Pseudomonadaceae and Pasturellaceae seem to be dominant. Furthermore, a considerably 
greater bacterial diversity within sputa may be observed in comparison to cultures, with the 
presence of less abundant and potentially more difficult-to-culture bacterial genera being 
detected including anaerobic Prevotellaceae, Veillonellaceae and Actinomycetaceae [15,43]. 
Most microbiome studies in bronchiectasis to date have been small, and therefore the clinical 
importance of this information is uncertain.  
Few data have been published regarding the prevalence of fungal colonization. The prevalence 
of at least one isolation of Aspergillus spp has been found between 2% and 24%, whereas one 
study found Candida in 45% of samples [4,41,44]. The prevalence of isolation of Aspergillus spp 
and Candida in more than two sputum samples taken at least 6 months apart was observed in 
8.7% and 34%, respectively [44]. It is now possible to perform sequencing of the fungal 
“mycobiome” in a similar way to that described above for bacteria, and such studies will help to 
answer whether fungal colonization has clinical relevance. The prevalence of non-tuberculous 
mycobacteria (NTM) in Europe is lower than 10%, although there seems to be a broad 
geographic variation in prevalence [45]. Whilst this may reflect variation in sampling frequency 
it is highly likely there are environmental factors that play a role in this. The role of NTM 
between innocent colonizers or those causing chronic infection and the predisposing factors to 
this needs to be differentiated. Finally, there is a paucity of data regarding the isolation of 
viruses and multi-resistant bacteria [16]. The prevalence of methicillin-resistant S. aureus was 
1.3% in the study by Chalmers and co-workers, whereas multiresistant Gram-negative bacteria 
were 4.5% [35].  
Given this knowledge gap in Europe, multicentre studies with a large number of patients are 
needed to find out the real prevalence of airway pathogens across Europe, as well as data 
relating to the microorganisms that are implicated and antibiotic sensitivity patterns. 
Longitudinal studies will be required to study the factors that may have an influence on regional 
differences and the role of anaerobic bacteria, multi-resistant bacteria, virus, NTM and fungi in 
chronic infection and exacerbations. Finally, it is also desirable that agreed definitions of 
important concepts such as initial colonization, intermittent isolation, chronic colonization, 
chronic infection, eradication, and exacerbation should be adopted across Europe.  
Consensus statements: 1) We suggest studies of the microbiome (incorporating bacteria and 
potentially fungi) in bronchiectasis linked to detailed clinical phenotyping data; 2) A 
longitudinal study of the bacteriology of bronchiectasis incorporating data on antibiotic 
resistance is needed. 
  
4. What is the impact of long-term antibiotic therapy on microbial resistances? 
 
The wide use of both systemic and inhaled antibiotics in patients with bronchiectasis causes 
rising concern about antimicrobial resistance, particularly for P. aeruginosa whose rate of 
resistance to ciprofloxacin could grow along with its spread [46,47]. Factors associated with the 
risk of antibiotic resistance may be antibiotic-related (type of antibiotic, frequency, doses, 
duration, local concentration) and pathogen-related (hypermutation, biofilm production) [48-
51]. Since few options are currently available to intervene on microbial characteristics, most of 
the current efforts are dedicated to improve antibiotics characteristics and to optimize their 
administration. New formulations, such as dry powder or liposomal solution for inhalation, and 
new molecules are being investigated in order to improve antibiotic tolerance and efficacy [52]. 
Targeting such drugs to the lung may limit the development of resistance by avoiding affecting 
the enteric flora. Although recent guidelines recommend higher antibiotic doses and longer 
duration of therapy to treat exacerbations, it is still debated whether both a dual agent therapy 
(systemic plus inhaled antibiotic) and shorter duration can be preferable not only to improve 
clinical outcomes and reduce side effects, but also to minimise antimicrobial resistance [40,53-
55]. 
Regarding the use of long-term antibiotics, periodic administration of rotating or fixed 
antibiotics is potentially associated with increased resistance and side effects, and risk of 
selection of fungal infection [44,56-58]. Inhaled antibiotics have been traditionally administered 
in 28-day cycles because of a theoretical benefit in terms of lower resistance, although data 
comparing to continuous administration is lacking. Although prolonged therapy with macrolides 
is effective in reducing exacerbations, there is a clear risk of antibiotic resistance for both 
sputum and oropharyngeal flora and a more careful selection of patients undergoing this 
treatment is recommended [59-62]. Long term inhaled therapy offers clear advantages upon 
systemic antibiotics in both CF and non-CF bronchiectasis in terms of disease control and side 
effects, although clinical response and tolerability are quite variable [63,64]. The risk of 
antimicrobial resistance to inhaled antibiotics seems to be very low despite prolonged and 
continuous administration, perhaps due to the high concentrations achieved in the airways 
[36]. Nevertheless as the use of inhaled antibiotics increases, and as new inhaled antibiotics as 
licensed there is a need to carefully monitor antibiotic resistance rates emerging in existing 
pathogens or the selection of new inherently resistant organisms.  
A number of unresolved issues deserve attention for future research, including the possibility to 
evaluate longitudinal data on the acquisition of resistance for pathogens that chronically infect 
bronchiectasis patients. Furthermore, an evaluation of risk factors, both host-, antibiotic- and 
pathogen-related, leading to antibiotic resistance should be adequately conducted.  
Consensus statements: 1) Longitudinal studies should be conducted in patients receiving oral 
and inhaled antibiotics to monitor for the emergence of antibiotic resistance; 2) Studies 
should ideally evaluate whether cyclical or continuous administration of long-term antibiotics 
is superior both in terms of clinical efficacy and the emergence of resistance. 
 
 
 5. When should a long-term suppressive antibiotic therapy (either oral or inhaled/nebulized) be 
started in patients with bronchiectasis (according to the presence or not of P. aeruginosa or 
other pathogens) and what should be the endpoints for efficacy? 
 
Long-term suppressive antibiotic treatment is increasingly used to treat chronic bronchial 
infection. Several reports describe the chronic use of inhaled antibiotics in about 10% and of 
macrolides in about 30% of all bronchiectasis patients [65-68]. The use of inhaled antibiotics 
has been predominantly in patients with P. aeruginosa colonization with limited data in 
patients with other pathogens [69].  
Various inhaled antibiotics have been tested to reduce bacterial load from bronchiectasis 
patients’ airways and related symptoms and exacerbations such as tobramycin [70,71], colistin 
[72], gentamicin [69], and aztreonam [73]. Despite some differences among trials and 
antibiotics (duration, doses, etc.) inhaled antibiotics have demonstrated to be safe and 
efficacious in reducing the sputum bacterial density, increase P. aeruginosa eradication and 
attenuate the risk of exacerbation in cystic fibrosis, however, although some risk of wheeze and 
bronchospasm has to taken into account [64]. In bronchiectasis data are more limited and 
results have been mixed.  Aztreonam failed to demonstrate any improvement in quality of life 
or exacerbations in two phase 3 trials, while colistin narrowly failed to reach its primary end-
point of time to next exacerbation, although achieved a significant improvement in health 
related quality of life and improved exacerbations in those compliant with therapy. Gentamicin 
was evaluated in a small, randomised, single-blinded study of 57 patients compared to 0.9% 
saline and caused a significant reduction in bacterial load and exacerbations.  
Tolerability can be a major issue with inhaled antibiotics in bronchiectasis, with an increase in 
adverse events in the aztreonam trials, and a number of other trials. As a result of the 
challenges in these trials, none are as yet licensed for use in bronchiectasis by authorities in 
Europe or the United States. At the time of writing, large phase 3 trials of two formulations of 
pulmonary-targeted ciprofloxacin are ongoing. 
With regards to oral long-term macrolides, 3 different trials have largely demonstrated their 
usefulness in reducing the number of exacerbations with consequent improvement of quality of 
life and in some cases with slower lung function decline [59-61]. Nevertheless, it is important to 
remember several concerns about long-term use of macrolides: including antimicrobial 
resistance [61,74]; the potential to promote macrolide-resistant NTM [75-77] and an increased 
risk of cardiovascular complications has been reported [78,79]. In conclusion, it seems that 
macrolides are clearly beneficial in patients with bronchiectasis, but the optimal patient 
population to benefit has not been defined. The inclusion criteria of the trials were broad, 
including patients with 1 exacerbation [59], 2 exacerbations [61] or 3 exacerbations [60] in the 
previous year and each trial used a different regimen (azithromycin 500mg three times per 
week or 250mg daily, or erythromycin ethylsuccinate 400mg bd). Trials had either 6-month [59] 
or 12-month [60,61] treatment duration and the long-term safety and resistance impact of 
these drugs is unknown.  
Consensus statements: 1) Further studies are required to define the optimal patient 
population to benefit from long-term macrolide therapy; 2) More “real world” data on the 
long-term safety and resistance impact of macrolide treatment are required; 3) Inhaled 
antibiotics such as colistin and gentamicin should be subject to definitive phase III trials to 
demonstrate a reduction in exacerbations and improvements in quality of life. 
 
 
6. What are the key factors leading to P. aeruginosa colonization? 
 
The prognostic implications of P. aeruginosa colonization have already been discussed above. 
This relationship between P. aeruginosa and a worse phenotype is likely to be both cause and 
effect, with P. aeruginosa more likely to colonize patients with more severe disease, but studies 
also demonstrating an independent effect of P. aeruginosa on morbidity and mortality. The 
reason that some patients with bronchiectasis become colonized with P. aeruginosa while the 
majority do not is unexplained. Understanding why this happens is critical, given the clinical 
implications and the significant hospitalisation and other costs associated with the treatment of 
P. aeruginosa infections. 
Genetic studies may identify host risk factors for P. aeruginosa colonization, and a modest 
effect of Mannose binding lectin polymorphisms on susceptibility has been shown in 
bronchiectasis and in cystic fibrosis [80,81]. In addition to host factors, microbial factors are 
also important in P. aeruginosa colonization. In CF there is clear evidence of person-person 
transmission and epidemic strains have been well described in the literature leading to strict 
patient isolation [82]. Similar cross infections have not been demonstrated to date in non-CF 
bronchiectasis [83]. Different P. aeruginosa strains in CF have been recognized to have variation 
in in vitro phenotypes that appear to translate into clinically meaningful outcomes [84,85]. The 
concept of an airway polymicrobial community is being increasingly recognized and the 
interaction between various microbes and its impact on P. aeruginosa colonization is likely to 
provide further insights in the future.  
Large, longitudinal, observational studies should help answer many aspects of this research 
question. In particular, the assessment of a large cohort of patients at first P. aeruginosa 
colonization will help determine the risk factors for its development and a comparison of the 
clinical course pre and post colonization may help determine the independent impact that P. 
aeruginosa. Future cohort studies assessing the airway microbiome in patients with and 
without P. aeruginosa colonization may also provide clues as to how the complex microbial 
interactions can affect risk. Finally, multicentre P. aeruginosa genotyping and epidemiological 
studies may help answer the question of cross-infection and provide insights into the genotype-
phenotype- clinical outcomes associations with P. aeruginosa infection. 
Consensus statements: 1) Mechanistic studies investigating the genetic, microbiological, 
inflammatory and clinical susceptibility factors for P. aeruginosa colonization should be 
conducted; 2) Long-term cohort studies are needed to identify which patients acquire P. 
aeruginosa colonization and to identify its independent effects on outcome. 
 
 
7. What are the indications of oral versus inhaled/nebulized long-term suppressive antibiotic 
treatment?  
 
There are no head to head trials of oral versus inhaled antibiotics. The criteria to choose 
between oral macrolides and inhaled antibiotics are still not clear and the decision is still 
empirical and based on personal experience and local healthcare prescription rules. 
Nevertheless it is clear that some factors could justify the antibiotic choice such as the presence 
of specific antibiotic allergies and side effects, the patients’ preferences and ability to manage 
inhalations, the co-existence of rhinosinusitis (which may also benefit from macrolides) and 
cardiovascular comorbidities. In the absence of head to head trials, large registries should 
provide important information about treatment patterns. In addition, ongoing randomized 
trials of inhaled antibiotics which include macrolide-treated patients will evaluate the 
important question of whether inhaled antibiotics can provide added benefit.  
Consensus statement: Comparative studies are needed to determine the optimal choice 
between oral and inhaled antibiotic treatment in patients with and without P. aeruginosa 
colonization. 
8. What are the best molecule, dose, regimen and duration for long-term oral antibiotic therapy 
in patients with bronchiectasis (according to the presence or not of Pseudomonas aeruginosa or 
other pathogens)? 
 
Long-term oral antibiotic therapy has been a key part of clinical management for bronchiectasis 
for decades, with some limited evidence of efficacy from long-term beta-lactams in the 1980’s. 
Macrolides, however, have been favoured due to in vitro evidence that they have anti-
inflammatory and immunomodulatory effects in addition to their broad antimicrobial activity 
against pathogens found in bronchiectasis [86]. Three major studies recently demonstrated the 
efficacy of long-term macrolides in bronchiectasis in double-blind randomized trials [59-61].  
Key questions remain regarding oral antibiotic therapy including: Do macrolides have to be 
continued lifelong, or can they be withdrawn e.g. after 12 months? The most appropriate dose 
and macrolide agent to minimise side effects and development of antimicrobial resistance has 
not been determined. It is not known if alternative oral antibiotic agents such as tetracyclines 
or beta-lactams are equally effective when given long-term. As the maximum duration of 
macrolide treatment was 12 months, it is not known if the effectiveness of macrolides wanes 
over time as antibiotic resistance develops or if effectiveness is sustained. These questions may 
be addressed by controlled trials or by multicentre, international registries. 
Consensus statement: Randomized controlled trials should address whether alternative long-
term oral antibiotics (other than macrolides) are effective at reducing exacerbations.  
 
Important research priorities identified by patients 
 
Other important themes have been identified from the top ranking patient priorities with a 
special attention focused on condition management, communication and information. These 
areas were all strongly supported by the expert working group.  
 
1. Condition management 
The questionnaire identified a number of research topics that could help improve the 
management of their bronchiectasis. Over 96% of respondents felt that their bronchiectasis 
could be better managed through having a self-management plan co-designed with their HCP, 
and access to physiotherapy/pulmonary rehabilitation, which also includes teaching them how 
to use techniques/equipment at home [4,23,87,88]. Self-management plans facilitated by good 
communication between patients and HCPs empower patients to manage and cope with their 
condition more confidently and independently [89,90]. An important component of these self-
management strategies, and in reducing hospitalization, is the awareness of HCPs’ of 
bronchiectasis and available and appropriate community care and physiotherapy services 
[87,91]. Research into this area would evidence the effectiveness of self-management 
strategies to support their widespread implementation in bronchiectasis [90]. 
Consensus statement: Studies should be conducted to determine the effectiveness of patient 
self-management in bronchiectasis and adherence to treatment. 
 
2. Communication and information 
One of the top priorities for patients was good communication between HCPs and each patient. 
Patients also highly ranked the need for access to reliable plain language information on living 
with bronchiectasis [89]. This shows that patients’ do not feel their information needs are being 
met, as they are struggling to find accurate information to help them live with their condition, 
which is a role that can be supported by the clear communication of information to patients by 
HCPs, both at the point of diagnosis and as their condition/needs change [89]. Increasingly 
patients look to the internet for information on their condition; therefore healthcare 
professionals can provide an invaluable service by signposting patients and their carers/families 
to reliable plain language information both online and in paper format i.e. medically accurate, 
plain language information leaflets. This role can be especially important for people with 
bronchiectasis and other neglected and under-resourced conditions, where there is less public 
and healthcare professional awareness and few widely available multilingual information 
leaflets, patient organisations and support groups. The potential for enhanced information 
packages or patient alert systems to help adherence and self-management offers a potentially 
cost effective solution acceptable to patients, with examples available in other disease areas 
and with patients involved in the development of resources. 
 
Consensus statements: 1) Further research with patients as partners could explore the 
specific information needs of bronchiectasis patients, effective HCP and patient 
communication strategies, and develop improved patient-reported outcomes; 2) A 
multidisciplinary education programme is needed for bronchiectasis to increase awareness 
among non-specialists in secondary care and among primary care.  
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EXAMPLE OF PATIENTS’QUESTIONNAIRE 
Help shape the future of bronchiectasis research and treatment across Europe 
We are asking people with bronchiectasis, their families and friends to tell us what we should be 
looking at to provide answers to the challenges of treating and living with bronchiectasis.  
What do YOU think needs to change or be considered to have the greatest impact on quality of life 
for people with bronchiectasis?  
This survey is part of the work of EMBARC (European Multicentre Bronchiectasis Audit and 
Research Collaboration) to facilitate multidisciplinary collaborative research in non-cystic fibrosis 
bronchiectasis (www.bronchiectasis.eu).  
EMBARC is currently working on an action plan that describes what is needed to reduce the impact 
of bronchiectasis on you and on healthcare systems in Europe. Your answers will influence what 
research is done by these research centres in future.  
This survey will take up to 15 minutes to complete, and is anonymous. If you would like to receive 
updates or would like to become more involved in the project, you can enter your email address at 
the end of the survey. 
 
1. Are you…? A person with bronchiectasis A parent, relative or carer of someone with bronchiectasis 
Other (please specify) 
 2. What age are you? 
Under 18  
18-30  
31-50  
51-60  
61-70  
Over 70 
 
3. Are you..?  
Male  
Female 
 
4. In which country do you live? 
 
5. What aspect of your / your partner or relative’s bronchiectasis do you/they find the most difficult 
to manage? 
 Not an issue Not very 
difficult 
Difficult Very 
difficult 
No 
opinion 
Cough       
Sputum (mucus/phlegm from the 
lungs) 
     
Coughing up blood      
Shortness of breath       
Not feeling fit or having the strength 
to do daily activities, such as walking 
far, doing housework, shopping, 
hobbies  
     
Tiredness       
Sleeping problems       
Weight loss       
Anxiety       
Depression      
Fever      
Exacerbations (episodes of 
increased sputum (mucus) or 
     
change in its colour, new or 
increased shortness of breath 
and/or fever that lead you to go to 
the doctor)  
Emergency hospital admission       
Other (please specify)      
 
6. To manage bronchiectasis well it is important to understand the disease. How important do you 
think the following areas of research are to improve how bronchiectasis is managed by doctors? 
 Unimportan
t 
Not very 
important  
Important Very 
importan
t 
No 
opinio
n 
To identify how often and why 
bronchiectasis occurs in certain 
groups of people across Europe 
     
To identify the cause(s) of 
bronchiectasis  
     
To identify how bronchiectasis 
develops and continues 
     
To identify what makes some 
patients’ bronchiectasis get worse  
     
To understand the relationship 
between bronchiectasis and other 
medical conditions, such as asthma, 
‘acid’ reflux, inflammatory bowel 
diseases  
     
To explore the link between getting a 
cold (for example rhinovirus) and 
having an exacerbation To identify 
triggers for an exacerbation  
     
To identify triggers for an 
exacerbation  
     
To find ways to diagnose 
bronchiectasis earlier, such as by 
local doctors 
     
Testing new techniques for 
managing bronchiectasis in real 
world environments, such as at 
home and community settings (not 
in the laboratory or in hospitals) 
     
 
7. Each person’s bronchiectasis can affect them differently. This makes it difficult to know which is the 
best treatment. How important do you think the following areas are to help improve how 
bronchiectasis is treated? 
 Unimportan
t 
Not very 
important  
Important Very 
importan
t 
No 
opinio
n 
To develop better ways of teaching 
people to use their medicines  
     
To develop medicines that can be 
taken in different ways, such as for 
inhaled or nebulised 
     
Using longer-term antibiotic therapy 
when a person’s condition is stable  
     
Using vaccines to prevent 
exacerbations  
     
Knowing more about the role of 
physiotherapy and pulmonary 
rehabilitation (a short course of 
regular exercise sessions and 
education sessions)  
     
Educating primary care doctors to 
prescribe the same dose/length of 
antibiotic therapy for exacerbations 
in bronchiectasis as used in cystic 
fibrosis  
     
To improve awareness of 
bronchiectasis in community care 
services, for example among 
community-based nurses and 
physiotherapists 
     
 
8. Bronchiectasis is such a complex condition that there is currently no agreed best way to look for 
changes. How important do you think the following areas are to improve how each person’s 
bronchiectasis is monitored? 
 Unimportan
t 
Not very 
important  
Important Very 
importan
t 
No 
opinio
n 
Having regular lung function testing 
to help notice changes or increased 
risk of an exacerbation 
     
Having the equipment at home to      
monitor symptoms  
Having regular computed 
tomography (CT) scans to look for 
changes or increased risk of an 
exacerbation  
     
Regular sputum examinations when 
a person is stable and during an 
exacerbation to learn more about 
how the condition changes  
     
Being able to monitor and treat the 
coughing up of blood  
     
Being able to identify people at 
increased risk of poor outcomes or 
needing urgent treatment for their 
bronchiectasis 
     
 
 
9. Education, technology and self-awareness, known as self-management, can help each person gain 
greater control over their bronchiectasis by reducing exacerbations and improving how well they 
feel. How important do you think the following areas are in improving self-management throughout 
life? 
 Unimportan
t 
Not very 
important  
Important Very 
importan
t 
No 
opinio
n 
Good communication between 
healthcare professionals and each 
person with bronchiectasis  
     
Having a self-management 
programme and care plan designed 
with each person to help them have 
greater control over their condition 
and recognise/manage an 
exacerbation  
     
Ensuring each person has access to a 
home intravenous (IV) antibiotic 
service to avoid unnecessary 
hospital admissions  
     
Using peer support forums and 
social media to exchange 
information with others  
     
Providing each person with copies of 
their test results so they can keep a 
     
useful history of the progress of their 
own condition 
Having access to reliable, easy to 
understand information about 
different aspects of living with 
bronchiectasis  
     
Having access to physiotherapy and 
being taught the techniques and how 
to use the equipment at home 
     
 
10. Are there any other areas that you think should be researched in the field of bronchiectasis? 
 
11. If you would like to receive updates on the project or get involved and represent others with 
bronchiectasis, please enter your email address. 
 
If you have any comments or questions, email Sarah Masefield 
(sarah.masefield@europeanlung.org) at the European Lung Foundation (ELF). Thank you very 
much for your time and participation in this project. 
